14.69  0.98 (7.15%)		06-09 16:00
Open: 13.9 High: 14.73 Volume: 2,270,236		Pre. Close: 13.71 Low: 13.7901 Market Cap: 4,686(M)

Short term
Mid term
Targets	6-month :	17.2	1-year :	20.09
Resists	First :	14.72	Second :	17.2
Pivot price	12.97
Supports	First :	12.89	Second :	11.76
MAs	MA(5) :	13.7	MA(20) :	12.78
	MA(100) :	13.19	MA(250) :	11.38
MACD	MACD :	0.3	Signal :	0
%K %D	K(14,3) :	93.7	D(3) :	90.8
RSI	RSI(14): 72.7
52-week	High :	15.42	Low :	7.66

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ AMRX ] has closed above the upper band by 12.0%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 61% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	14.75 - 14.81	14.81 - 14.86
Low:	13.64 - 13.7	13.7 - 13.76
Close:	14.56 - 14.68	14.68 - 14.79

Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.

Tue, 09 Jun 2026
Amneal Pharmaceuticals, Inc. (AMRX) Latest Stock News & Headlines - Yahoo Finance

Tue, 09 Jun 2026
Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase - TradingView

Tue, 09 Jun 2026
What's Driving Amneal's 2026 Growth Outlook? - TradingView

Sat, 06 Jun 2026
A Look At Amneal Pharmaceuticals (AMRX) Valuation After Romidepsin Approval And Positive CREXONT Trial Data - Sahm

Fri, 05 Jun 2026
Amneal Stock Up on FDA Nod for Romidepsin Injection Solution - The Globe and Mail

Fri, 05 Jun 2026
Amneal Pharmaceuticals Reports Positive Interim Data from Phase 4 ELEVATE-PD Study Demonstrating Benefits of CREXONT in Parkinson's Disease Patients - Quiver Quantitative

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	319 (M)
Shares Float	178 (M)
Held by Insiders	44.1 (%)
Held by Institutions	52 (%)
Shares Short	7,960 (K)
Shares Short P.Month	8,560 (K)

EPS	0.37
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.15
Profit Margin	4 %
Operating Margin	19.5 %
Return on Assets (ttm)	8.3 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	3.9 %
Gross Profit (p.s.)	3.73
Sales Per Share	9.56
EBITDA (p.s.)	2.09
Qtrly Earnings Growth	384.6 %
Operating Cash Flow	306 (M)
Levered Free Cash Flow	101 (M)

PE Ratio	39.7
PEG Ratio	0
Price to Book value	-104.93
Price to Sales	1.53
Price to Cash Flow	15.32

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.